公开(公告)号：US11466076B2

公开(公告)日：2022-10-11

申请号：US16098085

申请日：2017-04-28

申请人： UCB BIOPHARMA SPRL

发明人： Ralph Adams ,  Sam Philip Heywood

IPC分类号： C07K16/00 ,  C07K16/18 ,  C07K14/76 ,  C07K14/765 ,  C07K16/06 ,  A61K39/395 ,  A61K39/00 ,  C07K16/46

摘要： The present disclosure relates to a method of modulating the half-life of a binding domain specific to a serum carrier protein by mutating the sequence and a modulated binding domain specific to a serum carrier protein.

公开(公告)号：US20170275355A1

公开(公告)日：2017-09-28

申请号：US15476279

申请日：2017-03-31

申请人： UCB BIOPHARMA SPRL

发明人： Ralph Adams ,  Andrew George Popplewell ,  Stephen Edward Rapecki ,  Simon Peter Tickle

IPC分类号： C07K16/24 ,  C07K16/46 ,  A61K39/00

CPC分类号： C07K16/244 ,  A61K47/60 ,  A61K2039/505 ,  C07K16/464 ,  C07K2317/20 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

摘要： The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.

公开(公告)号：US20160039929A1

公开(公告)日：2016-02-11

申请号：US14795374

申请日：2015-07-09

申请人： UCB Biopharma SPRL

发明人： Richard Evan Gelinas ,  Mitra Choudhury Singhal ,  Yi Zhang ,  Andrew George Popplewell ,  Ralph Adams

IPC分类号： C07K16/24

CPC分类号： A61K39/3955 ,  A61K2039/505 ,  C07K16/248 ,  C07K2316/96 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/11

摘要： The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

摘要翻译： 本发明涉及对IL-6的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途以及产生所述抗体分子的方法。

公开(公告)号：US20180346561A1

公开(公告)日：2018-12-06

申请号：US15974407

申请日：2018-05-08

申请人： UCB BIOPHARMA SPRL

发明人： Ralph Adams ,  Terence Seward Baker ,  Alastair David Griffiths Lawson

IPC分类号： C07K16/24

CPC分类号： C07K16/244 ,  C07K2317/33 ,  C07K2317/92

摘要： The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

公开(公告)号：US09803004B2

公开(公告)日：2017-10-31

申请号：US14356181

申请日：2012-11-09

申请人： UCB Biopharma SPRL

发明人： Ralph Adams ,  Pallavi Bhatta ,  Sam Philip Heywood ,  David Paul Humphreys

IPC分类号： C07K16/18 ,  C07K16/28

CPC分类号： C07K16/18 ,  C07K16/2878 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/624 ,  C07K2317/92

摘要： A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 or SEQ ID NO:2 and/or comprising a light chain variable domain having the sequence given in SEQ ID NO:3 or SEQ ID NO:4, in particular comprising a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 1 and SEQ ID NO:3 or a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 2 and SEQ ID NO:4. The disclosure also extends to polynucleotides encoding the antibodies or fragments, vectors comprising same and host cells capable of expressing the polynucleotides. The disclosure further includes pharmaceutical compositions comprising the antibodies or fragments and therapeutic used of any one of the same.

公开(公告)号：US20150218271A1

公开(公告)日：2015-08-06

申请号：US14690892

申请日：2015-04-20

申请人： UCB Biopharma SPRL

发明人： Ralph Adams ,  Terence Seward Baker ,  Alastair David Griffiths Lawson

IPC分类号： C07K16/24

CPC分类号： C07K16/244 ,  C07K2317/33 ,  C07K2317/92

摘要： The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

摘要翻译： 本发明涉及对IL-17A和IL-17F的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途和产生所述抗体分子的方法。

公开(公告)号：US10308723B2

公开(公告)日：2019-06-04

申请号：US15482260

申请日：2017-04-07

申请人： UCB BIOPHARMA SPRL

发明人： Ralph Adams ,  Andrew George Popplewell ,  Stephen Edward Rapecki

IPC分类号： A61K39/395 ,  C07K16/46 ,  C07K16/24

摘要： The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

公开(公告)号：US09988446B2

公开(公告)日：2018-06-05

申请号：US14690892

申请日：2015-04-20

申请人： UCB Biopharma SPRL

发明人： Ralph Adams ,  Terence Seward Baker ,  Alastair David Griffiths Lawson

IPC分类号： A61K39/395 ,  C07K16/24

CPC分类号： C07K16/244 ,  C07K2317/33 ,  C07K2317/92

摘要： The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

公开(公告)号：US20160319003A1

公开(公告)日：2016-11-03

申请号：US15143162

申请日：2016-04-29

申请人： President and Fellows of Harvard College ,  UCB Biopharma SPRL

发明人： Gökhan S. Hotamisligil ,  Mehmet F. Burak ,  Feyza Engin ,  Scott B. Widenmaier ,  Elisabeth Helen Roberts ,  Adrian Richard Moore ,  Carl Brendan Doyle ,  Ralph Adams ,  Karine Jeannine Madeleine Hervé ,  Shauna Mhairi Wales ,  Kerry Louise Tyson

IPC分类号： C07K16/18

CPC分类号： C07K16/18 ,  A61K39/00 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/6018 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/70 ,  C07K2317/76 ,  C07K2317/92

摘要： This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as “aP2”) for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.

摘要翻译： 本发明涉及改进的抗αP2抗体和抗原结合剂及其组合物，其靶向脂质伴侣aP2 / FABP4（称为“aP2”），用于治疗疾病如糖尿病，肥胖症，心血管疾病 ，脂肪肝疾病和/或癌症等。 一方面，公开了aP2介导的疾病的改进治疗，其中血清aP2是靶向的，并且使用低结合亲和性aP2单克隆抗体中和或调节aP2的生物学活性，提供较低的空腹血糖水平，改善的全身葡萄糖代谢，增加 全身胰岛素敏感性，脂肪量减少，肝脂肪变性减少，心血管疾病降低和/或发生心血管疾病风险降低。

公开(公告)号：US20210301012A1

公开(公告)日：2021-09-30

申请号：US16342800

申请日：2017-10-23

申请人： UCB Biopharma SPRL

发明人： Michael John Wright ,  Ralph Adams ,  Rebecca Burnley ,  Anna Ettorre

IPC分类号： C07K16/24

摘要： The invention is in the field of protein:protein interactions, in particular the stabilisation of protein:protein interactions. Binding proteins are provided for stabilising the interactions, together with compositions comprising the binding proteins. Methods using the binding proteins are also provided, including targeting of cells and also medical uses.